Actualités

NKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-stage studies advance in autoimmune diseases.

While Eli Lilly isn't a perfect technical setup, it's still a fundamental powerhouse that could be worth considering.

Eli Lilly’s second quarter was marked by a positive market reaction, despite the company missing Wall Street’s revenue expectations. Management credited growth in key products—especially in cardiometabolic health, oncology, and neuroscience—as drivers of performance. CEO David Ricks pointed to “robust revenue growth across all Key Products and major geographies,” noting the strength of new medicines and expansion in emerging markets. The launch of Foundayo in the U.S. and UAE, along with ongoing

AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

Revenue surged 48% on Mounjaro and Zepbound demand, with full-year guidance raised.

Moby summary of Absci Corporation's Q2 2026 earnings call

Absci (NASDAQ:ABSI) outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis, while reporting a larger cash balance following a June equity offering and strategic investment from El

Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the stock well past current targets.

Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance. Chair and CEO Dave Ricks said the company delivered gr

The S&P 500 and Dow Jones hit highs while the Nasdaq raced above key levels as oil prices and yields fell. Palantir, Cloudflare and SpaceX were big movers amid earings.

In early August 2026, CVS Health reported second-quarter results showing higher sales of US$35,117 million and revenue of US$106.10 billion, alongside net income of US$2,979 million and materially higher earnings per share versus a year earlier. On the same day, CVS Health also raised its 2026 earnings guidance and expanded its GLP-1 weight management offering through a new collaboration with Eli Lilly, underscoring how integrated pharmacy, insurance and care-delivery assets can be combined...

Eli Lilly recently reported that second-quarter 2026 sales rose to about US$23.0 billion with net income of roughly US$7.10 billion, and the company raised its full-year 2026 revenue guidance to US$85.0 billion–US$87.0 billion from US$82.0 billion–US$85.0 billion. Management attributed this step-up in outlook largely to surging demand for its GLP-1 diabetes and weight-loss portfolio, reinforcing how central these products have become to Lilly’s overall earnings power. With Lilly lifting 2026...

Lilly lifts its 2026 outlook as Foundayo adoption accelerates, Medicare expands obesity access and retatrutide advances toward a 2027 filing.

Eli Lilly and Company will release its second-quarter earnings report before the opening bell on Wednesday, Aug. 5. Analysts expect the company to report quarterly earnings of $6.58 per share, up from $6.31 per share in the year-ago period. The...

Moby summary of Eli Lilly and Company's Q2 2026 earnings call

As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as healthcare names combining resilient business models with strong earnings momentum.

Moby summary of Charles River Laboratories International, Inc.'s Q2 2026 earnings call

Eli Lilly and Co (LLY) raises full-year 2026 guidance after Q2 revenue jumps 48%, driven by blockbuster incretin sales and strong international expansion.

Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.

Today's ADP private-sector payrolls came in below the +75K forecast and less than half the downwardly revised +95K from June.

Investors have plenty of reasons to be uncertain right now. But that has not wholly shaken companies' faith in their ability to deliver strong earnings growth this year.

The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

The S&P 500 climbed 0.6% on Wednesday, while SpaceX stock slumped more than 10% on its first quarterly report since going public

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively trad

The benchmark US stock measures were trending higher in Wednesday's premarket activity amid growing

Eli Lilly posted a blockbuster second quarter fueled by continued demand for its portfolio of GLP-1 medications. The world’s biggest drugmaker by market value reported adjusted earnings of $8.38 a share in the period, better than the $6.01 consensus estimate among analysts polled by FactSet. Revenue surged 48% to nearly $23 billion—Wall Street was looking for $20.7 billion.

Investing.com -- Eli Lilly shares jumped more than 5% in premarket trading Wednesday after the U.S. pharma giant raised its annual revenue guidance amid strong demand for its popular weight-loss and diabetes drugs.

Mounjaro revenue jumped 91% to $9.9 billion and Zepbound brought in $4.9 billion as the drugmaker beat Wall Street estimates

CVS beat Wall Street expectations by a wide margin in the second quarter and raised its full-year profit forecast to as much as $8.10 per share

Investing.com -- CVS Health shares jumped about 5% in premarket trading Wednesday after the company raised its full-year profit guidance following better-than-expected second-quarter results.